Live Quote · NASDAQMDGLHealthcare · Biotechnology

Madrigal Pharmaceuticals, Inc.

$501.02▲ 0.23%(+$1.17)

TickerSpark Score

66/100

▌ Solid

53

Valuation

40

Profitability

100

Growth

76

Health

60

Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDGL research report →

52-Week Range66% of range

Low

$275.00

Current

$501.02

High

$615.00

Company Overviewwww.madrigalpharma.com

About the company

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH).

CEO: William J. Sibold
IPO: 2007
Employees: 528
HQ: West Conshohocken, PA, US

Price Chart

+78.72% · this period

Valuation

Market Cap: $11.55B
P/E: -47.01
P/S: 10.20
P/B: 26.77
EV/EBITDA: -41.50
Div Yield: 0.00%

Profitability

Gross Margin: 93.07%
Op Margin: -27.68%
Net Margin: -27.32%
ROE: -50.15%
ROIC: -35.20%

Growth & Income

Revenue: $958.40M · 432.05%
Net Income: $-288,284,000 · 38.12%
EPS: $-12.85 · 41.32%
Op Income: $-300,097,000
FCF YoY: 58.42%

Performance & Tape

52W High: $615.00
52W Low: $275.00
50D MA: $510.31
200D MA: $492.73
Beta: -1.06
Avg Volume: 313.26K

Get TickerSpark's AI analysis on MDGL

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

Date	Insider	Role	Type	Shares	Value
Jun 1, 26	Soergel David	officer: Chief Medical Officer	sell	1,042	$516.56K
May 22, 26	Levy Richard S	director	sell	40	$20.27K
May 22, 26	Levy Richard S	director	sell	320	$162.64K
May 22, 26	Levy Richard S	director	sell	151	$77.06K
May 22, 26	Levy Richard S	director	sell	610	$311.95K
May 22, 26	Levy Richard S	director	sell	439	$224.99K
May 22, 26	Levy Richard S	director	sell	40	$20.52K
May 22, 26	Levy Richard S	director	sell	343	$176.53K
May 22, 26	Levy Richard S	director	sell	657	$338.96K
May 22, 26	Levy Richard S	director	sell	723	$373.69K

Coverage · MDGL

Our MDGL coverage

Recent articles, reports, and earnings notes.

View all →

IPO

Should You Buy the Palatin Technologies IPO? Here's the Setup

Palatin Technologies, Inc. (NASDAQ: PTN) is expected to list on May 29, 2026, but the price range has not been disclosed. The company is not a traditional IPO: it is a long-public biotech moving to Nasdaq via a resale registration tied to warrant exercises. The bull case is pipeline leverage in obesity and rare disease; the bear case is dilution, losses, and a very tight cash position.